DRIO.NASDAQDariohealth CORP
10-Q: DarioHealth Q2 2025: Debt Refinanced Amidst Rising Losses
Sentiment:
Quarterly Report
DarioHealth Corp. refinanced its debt facility and reduced operating expenses in Q2 2025, but reported increased net losses attributable to common shareholders and faces substantial doubt about its ability to continue as a going concern.
Delay expectedThe company has faced timeline extensions in certain projects due to tariff-related pressures, impacting both hardware sourcing and partner-side execution.Some medical devices and hardware components are manufactured in China, and changes in trade policy have led to prolonged decision-making cycles and implementation delays for potential partners.
Capital raiseThe company explicitly states it "will continue to be dependent on raising additional funds to fund its operations" and that its "current cash on hand will not be sufficient to fund our projected operating requirements for a period of one year."As of June 30, 2025, the company did not meet a financial covenant under the Callodine Credit Agreement and notified Callodine of its intention to utilize an "Equity Cure" by November 15, 2025. An equity cure involves the issuance of additional Equity Interests and/or Subordinated Debt.The company has historically financed operations primarily through private placements and public offerings of common stock and warrants, receiving aggregate net proceeds totaling $289.74 million as of June 30, 2025.In December 2024 and January 2025, the company issued Series D, D-1, D-2, and D-3 preferred shares, raising approximately $18.805 million and $6.800 million in gross proceeds, respectively.
Worse than expectedNet loss attributable to common shareholders significantly increased by 131.2% for the six months ended June 30, 2025.The company explicitly states "substantial doubt about our ability to continue as a going concern" due to insufficient cash to fund operations for one year.A financial covenant under the new Callodine Credit Agreement was not met as of June 30, 2025, requiring an equity cure by November 15, 2025.
Summary
- Total revenues for the six months ended June 30, 2025, increased by 0.9% to $12.121 million, compared to $12.013 million in the prior year period, primarily driven by an increase in consumer channel revenues.
- Gross profit for the six months ended June 30, 2025, increased by 31.9% to $6.846 million (56.5% of revenues) from $5.188 million (43.2% of revenues) in the prior year, due to changes in revenue mix and lower amortization.
- Operating expenses significantly decreased by 35.1% to $25.455 million for the six months ended June 30, 2025, from $39.234 million in the prior year, driven by efficiency and post-merger integration activities.
- Net loss for the six months ended June 30, 2025, increased by 6.9% to $22.217 million, compared to $20.785 million in the prior year.
- Net loss attributable to common shareholders for the six months ended June 30, 2025, significantly increased by 131.2% to $32.628 million, from $14.113 million in the prior year, largely due to deemed dividends related to preferred stock.
- Cash and cash equivalents decreased to $21.954 million as of June 30, 2025, from $27.764 million on December 31, 2024.
- The company refinanced its existing $30 million credit facility with a new $32.5 million Callodine Loan Facility, with an additional $17.5 million available based on certain thresholds.
- As of June 30, 2025, the company did not meet one financial covenant under the new Credit Agreement but notified the lender of its intention to utilize an equity cure by November 15, 2025, which was waived by Callodine subject to successful implementation.
- The company added 21 new clients year-to-date, including 1 top U.S. healthcare institution, 2 regional health plans, and 18 employers, progressing towards its 2025 goal of 40 new clients.
Sentiment
Score: 3
Explanation: While operating expenses decreased and gross profit improved, the significant increase in net loss attributable to common shareholders, the explicit 'going concern' warning, and the breach of a debt covenant indicate severe financial distress and high uncertainty regarding future operations and liquidity. The debt refinancing provides some short-term relief but does not resolve the underlying cash burn and profitability issues.
Positives
- Gross profit increased by 31.9% to $6.846 million for the six months ended June 30, 2025, with gross margin improving to 56.5% from 43.2% in the prior year.
- Operating expenses decreased significantly by 35.1% to $25.455 million for the six months ended June 30, 2025, reflecting efficiency gains and post-merger integration.
- Net cash used in operating activities decreased by 48.1% to $12.704 million for the six months ended June 30, 2025, indicating improved operational cash burn.
- Successfully refinanced the existing $30 million credit facility with a new $32.5 million Callodine Loan Facility, extending the maturity to April 2030 and deferring debt amortization from end of 2025 to 2028.
- Added 21 new clients year-to-date, including a top U.S. healthcare institution, two regional health plans, and 18 employers, progressing towards the 2025 goal of 40 new clients.
- Published new research in the Journal of Medical Internet Research (JMIR) demonstrating the effectiveness of personalized digital health interventions for flu vaccine awareness.
- Unveiled new clinical research demonstrating the ability to sustain outcomes post-GLP-1 treatment and accurately predict blood glucose levels using AI.
- Entered a strategic commercial agreement with GreenKey Health to expand integrated chronic condition management solutions into the sleep apnea market.
Negatives
- Net loss attributable to common shareholders significantly increased by 131.2% to $32.628 million for the six months ended June 30, 2025, compared to $14.113 million in the prior year, primarily due to deemed dividends from preferred stock.
- Total financial expenses, net, increased substantially to $3.586 million for the six months ended June 30, 2025, from financial income of $11.267 million in the prior year, mainly due to revaluation of pre-funded warrants and long-term loan.
- Cash and cash equivalents decreased to $21.954 million as of June 30, 2025, from $27.764 million on December 31, 2024.
- Net cash provided by financing activities decreased to $6.939 million for the six months ended June 30, 2025, compared to $20.206 million in the prior year, indicating reduced capital raising.
- Revenues for the three months ended June 30, 2025, decreased by 14.2% to $5.369 million, compared to $6.255 million in the prior year, primarily due to a decrease in revenues from the pharma channel.
Risks
- Substantial doubt about the ability to continue as a going concern for twelve months from the date of issuance of the interim financial statements, as current cash on hand is not sufficient to fund projected operating requirements for one year.
- Revenues are concentrated with a major customer, which accounted for 16.4% of accounts receivable and 9.3% of Q2 2025 revenue, posing a risk if the agreement is terminated or performance fails.
- Operations in Israel expose the company to political, economic, and military instability, including ongoing armed conflicts and potential regional escalation, which commercial insurance does not cover.
- Significant changes in U.S. laws or policies, including trade policies and tariffs, may adversely affect the business, increasing manufacturing costs and causing timeline extensions and implementation delays due to hardware sourcing from China.
- Breach of financial covenants under the Credit Agreement as of June 30, 2025, which, if not cured by an equity cure by November 15, 2025, could lead to increased interest rates or acceleration of debt.
- The market price of common stock has been extremely volatile, fluctuating from $1.53 to $0.53 per share between January 1, 2025, and August 10, 2025, and may continue to be volatile due to factors beyond control.
- The low stock price may imply a negative valuation of intangible assets and goodwill, potentially resulting in impairment.
- Risk of delisting from Nasdaq due to the common stock bid price remaining below $1.00, with an extension to regain compliance until September 15, 2025.
Future Outlook
The company expects to incur future net losses and its transition to profitability is dependent upon successful development and commercialization of products and achieving sufficient revenues to support its cost structure. It will continue to depend on raising additional funds to fund operations, with no assurances of obtaining adequate financial resources for long-term development and commercialization. The current cash on hand is not sufficient to fund projected operating requirements for one year, raising substantial doubt about the ability to continue as a going concern. The company intends to continuously monitor its common stock bid price and is considering various measures, including a stock split, to regain Nasdaq compliance.
Management Comments
- "We are a leading global digital health company with a mission to power the behavior changes that drive better health."
- "We believe that most existing digital health solutions in the market fail to deliver improved health outcomes because users are not engaged due to a lack relevance, personalization, consumerization, and longitudinal data and information."
- "We believe that our D2C marketplace roots and continued focus delivers better user experiences, longer sustained engagement, stronger clinical outcomes, at the most affordable prices, that then delivers the highest return on investment (ROI) in the industry."
- "With the refinancing and current cash on hand, we believe that deferring the debt amortization from the end of 2025 to 2028 will allow the time to generate funds from operations to support our cash flow."
- "We notified Callodine of our intention to utilize an Equity Cure to address the event of default."
Industry Context
The company operates in the digital health and digital therapeutics (DTx) sector, focusing on personalized, evidence-based interventions for chronic conditions (diabetes, hypertension, obesity, musculoskeletal issues) and behavioral health (stress, anxiety, and depression). It emphasizes a "whole-person health" model integrating AI, data analytics, and one-on-one coaching, serving B2B2C channels (employers, health plans, pharmaceutical companies) and direct-to-consumer (D2C) markets. The company positions itself as a "digital health consolidation leader" through acquisitions like Twill, Inc., and is leveraging its platform for GLP-1 treatment optimization and expansion into new areas like sleep apnea, aligning with broader industry trends towards integrated, data-driven, and value-based healthcare solutions.
Comparison to Industry Standards
- The filing does not provide specific comparable companies, projects, or results to global benchmarks. While the company states it delivers the "highest return on investment (ROI) in the industry" and "most engaging and effective solutions" for certain demographics, these are self-assessments without external comparative data.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer, Treasurer and Secretary | NA | Chen Franco-Yehuda | 2025-05-15 | Appointment |
| Non-Executive Director | NA | Undisclosed (member of a consulting firm) | 2025-02-25 | Appointment |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Preferred Stock Terms Amendment | Amended and Restated Certificate of Designation for Series C, C-1, and C-2 Preferred Stock to extend mandatory conversion period from 15 to 24 months and introduce a 15% dividend on conversion shares for each full quarter anniversary of holding. | 2025-05-20 | Increases potential dilution for common shareholders and extends the period before preferred shares convert. |
| Lock-Up Agreement Amendment | Amended and Restated Lock-Up Agreement with Series B and C Preferred Stock holders, extending the restrictive period until February 21, 2026, in exchange for an additional 10% of common stock underlying their shares. | 2025-05-23 | Provides additional common stock to preferred holders, potentially increasing future dilution, but extends lock-up period. |
| Authorized Capital Increase | Amendment to Certificate of Incorporation to increase authorized Common Stock from 160,000,000 to 400,000,000 shares. | 2025-08-08 | Provides flexibility for future equity raises and stock-based compensation, but signals potential for significant future dilution. |
| Equity Incentive Plan Amendment | Amended and Restated 2020 Equity Compensation Plan to provide for an automatic annual increase in the share reserve (6% of fully diluted outstanding common stock from 2026-2030) and authorize Restricted Stock Units (RSUs). | 2025-07-23 | Increases potential future dilution from equity compensation but enhances flexibility for employee incentives. |
| Warrant Repricing Approval | Stockholders approved reducing the exercise price of certain warrants issued to Avenue Lenders to $0.7208 per share and permitting conversion of up to $2 million of loan principal at $0.8650 per share. | 2025-04-28 | Makes warrants more in-the-money and conversion more likely, increasing potential dilution for common shareholders. |
Related Party Transactions
- A new non-executive director, appointed on February 25, 2025, is a member of a consulting firm that has provided investment and business consulting services to the company since 2021.
- The consulting firm received approximately 258,000 shares of Common Stock and warrants to purchase up to 125,000 shares of Common Stock.
- The company pays the consulting firm a fixed monthly cash retainer of $10,000.
- Share-based compensation expenses related to this service provider amounted to $35,000 for the three months and $100,000 for the six months ended June 30, 2025.
Stakeholder Impact
- Shareholders face significant dilution risk from ongoing and potential future equity raises (preferred stock conversions, warrants, equity cure, increased authorized shares, equity compensation plan amendments). They experience a substantial increase in net loss attributable to common shareholders and high stock price volatility, with a risk of Nasdaq delisting.
- Employees benefit from stock-based compensation plans (options, restricted shares, RSUs). However, efficiency and post-merger integration activities led to a decrease in payroll expenses and headcount reductions.
- Customers benefit from new client additions, expansion into new health areas like sleep apnea, and continued development of AI-personalized digital health solutions.
- Creditors (Callodine Commercial Finance, LLC) have refinanced debt with extended maturity, but the company's breach of a financial covenant and 'going concern' warning indicate elevated credit risk, mitigated by the equity cure mechanism.
- Suppliers may face prolonged decision-making cycles and implementation delays due to tariff-related pressures affecting hardware sourcing and partner-side execution.
Next Steps
- Successfully implement an equity cure for the Callodine Credit Agreement covenant breach by November 15, 2025.
- Achieve certain revenue and gross margin thresholds to draw down an additional $2.5 million from the Callodine Loan Facility.
- Continue efforts to establish a stable recurring source of revenues sufficient to cover operating costs and achieve profitability.
- Monitor common stock bid price and consider measures, including a stock split, to regain Nasdaq compliance by September 15, 2025.
- Continue commercialization efforts for digital health products and solutions.
Key Dates
| Date | Description |
|---|---|
| 2011-08-11 | DarioHealth Corp. incorporated in Delaware and commenced operations. |
| 2011-09-14 | LabStyle Innovation Ltd. (wholly owned subsidiary) incorporated in Israel and commenced operations. |
| 2018-01-01 | Twill began expanding its offering to pharmaceutical companies. |
| 2022-06-09 | Entered into a Credit Agreement with OrbiMed Royalty and Credit Opportunities III, LP for a $50 million senior secured credit facility (Orbimed Loan). |
| 2022-01-01 | Entered first pharmaceutical company partnership. |
| 2023-05-01 | Refinanced former $25 million credit facility with a new $30 million Avenue Loan Facility; Orbimed Loan repaid. |
| 2023-07-01 | Earliest date for Discretionary Tranche of Avenue Loan Facility to be made available. |
| 2023-12-31 | Balance as of December 31, 2023. |
| 2024-02-15 | Acquired Twill, Inc.; entered First Amendment to Loan and Security Agreement and Supplement (Avenue Amendment); issued Pre-Funded Warrants as part of Twill acquisition. |
| 2024-02-16 | Entered Series C Purchase Agreements with accredited investors for Series C-2 Preferred Stock. |
| 2024-02-21 | Closing of Series C Preferred Stock, Series C-1 Preferred Stock and Series C-2 Preferred Stock occurred on or before this date. |
| 2024-03-10 | Filed Annual Report on Form 10-K for the year ended December 31, 2024. |
| 2024-06-25 | Stockholders approved the Avenue Amendment and repriced the Warrant to purchase Common Stock to $2.02 per share. |
| 2024-09-11 | Filed Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series B-3 Preferred Stock. |
| 2024-09-16 | Received written notice from Nasdaq regarding non-compliance with minimum bid price requirement ($1.00 per share). |
| 2024-11-01 | 2,500,100 Pre-Funded Warrants exercised into 2,499,828 shares of Common Stock. |
| 2024-12-16 | Entered into the Third Amendment to Loan and Security Agreement and Supplement with Avenue Lenders; issued Series D and D-1 preferred shares. |
| 2024-12-18 | Private placement transactions for Series D, D-1, D-2 and D-3 Preferred Stock closed. |
| 2025-01-01 | Company met the equity financing milestone for Avenue Loan Facility interest-only extension. |
| 2025-01-01 | Increased number of shares authorized for issuance under the 2020 Plan by 6,541,028 shares. |
| 2025-01-07 | Entered into Series D Purchase Agreements with accredited investors for Series D-2 and D-3 Preferred Stock. |
| 2025-01-14 | Closing of Series D-2 Preferred Stock and Series D-3 Preferred Stock occurred. |
| 2025-02-01 | 2,500,100 Pre-Funded Warrants exercised into 2,499,698 shares of Common Stock. |
| 2025-02-15 | New non-executive director appointed to the Board. |
| 2025-02-24 | Entered into a second amendment to the consulting agreement with a consulting firm. |
| 2025-03-01 | 1,675 shares of Series A-1 Preferred Stock converted into 779,601 shares of Common Stock. |
| 2025-03-17 | End of initial 180-calendar day compliance period for Nasdaq minimum bid price requirement. |
| 2025-03-18 | Received letter from Nasdaq approving an additional 180-calendar day extension to regain compliance with minimum bid price requirement. |
| 2025-04-28 | Held a special meeting of stockholders where they approved issuance of common stock for preferred stock conversions and dividends, and reduction of Avenue Lender warrant exercise price. |
| 2025-04-30 | Refinanced existing $30 million credit facility with a new $32.5 million Callodine Loan Facility; Avenue Loan Facility repaid in full. |
| 2025-05-01 | Announced closing of debt financing facility for up to $50 million provided by Callodine Commercial Finance, LLC. |
| 2025-05-15 | Chen Franco-Yehuda's appointment as Chief Financial Officer, Treasurer and Secretary became effective. |
| 2025-05-19 | Board of Directors approved the Authorized Capital Change. |
| 2025-05-20 | Filed Amended and Restated Certificate of Designation of Preferences, Rights and Limitations for Series C Preferred Stock, extending mandatory conversion period. |
| 2025-05-23 | Began entering into Amended and Restated Lock-Up Agreement with holders of Series B and C Preferred Stock. |
| 2025-05-28 | Ended entering into Amended and Restated Lock-Up Agreement with holders of Series B and C Preferred Stock. |
| 2025-05-01 | Announced new research published in JMIR demonstrating effectiveness of personalized digital health interventions for flu vaccine awareness. |
| 2025-06-01 | Announced a strategic commercial agreement with GreenKey Health to expand into the sleep apnea market. |
| 2025-06-01 | Unveiled new clinical research demonstrating ability to sustain outcomes post-GLP-1 treatment and accurately predict blood glucose levels using AI. |
| 2025-06-13 | Israel launched a preemptive strike targeting military and nuclear infrastructure inside Iran. |
| 2025-06-21 | United States military conducted targeted air strikes against three nuclear sites within Iran. |
| 2025-06-23 | Iran retaliated against U.S. interests in the region. |
| 2025-06-24 | A ceasefire was implemented between Iran and Israel. |
| 2025-06-30 | End of the quarterly period covered by the report. |
| 2025-07-23 | Stockholders approved the Amended and Restated 2020 Equity Compensation Plan. |
| 2025-07-23 | Stockholders voted to approve an amendment to the Certificate of Incorporation to increase authorized Common Stock from 160 million to 400 million shares. |
| 2025-08-07 | Common stock closing bid price reached a low of $0.53 per share. |
| 2025-08-08 | Amendment to the Certificate of Incorporation to increase authorized Common Stock took effect at 5:30 p.m. |
| 2025-08-10 | As of this date, 45,496,954 shares of common stock outstanding. |
| 2025-08-11 | Ceasefire between Iran and Israel still remains in place as of this date. |
| 2025-08-12 | Date of filing of the 10-Q report. |
| 2025-09-15 | Deadline to regain compliance with Nasdaq minimum bid price requirement. |
| 2025-09-30 | Trailing six-month period ending for potential additional six-month interest-only extension on Avenue Loan Facility (if milestone met). |
| 2025-11-15 | Deadline to successfully implement an equity cure for the Callodine Credit Agreement covenant breach. |
| 2026-02-21 | Extended restrictive period for Lock-Up Agreements until this date. |
| 2026-04-27 | One-third of Chen Franco-Yehuda's restricted shares vest. |
| 2026-12-31 | Warrants to certain consultants exercisable on or before this date. |
| 2027-05-01 | Original maturity date of Avenue Loan Facility. |
| 2027-11-01 | Extended maturity date of Avenue Loan Facility (if amended milestones met). |
| 2028-06-01 | Warrants to certain consultants exercisable on or before this date. |
| 2030-04-30 | Maturity date of Callodine Loan Facility. |
| 2030-12-31 | End of automatic annual increase in 2020 Plan share reserve. |
Recommendation
strong sellThe company faces severe financial challenges, including an explicit 'going concern' warning, a significant increase in net loss attributable to common shareholders, and a breach of a debt covenant requiring an equity cure. While operating expenses have been reduced and gross profit improved, these are overshadowed by the fundamental liquidity issues and the need for continuous capital raises, which are highly dilutive. The risk of Nasdaq delisting further compounds the investment risk. These factors collectively indicate a highly precarious financial position, making the stock a strong sell for investors.
Keywords
Digital health, Digital therapeutics, Chronic condition management, Behavioral health, Telehealth, AI, Healthcare technology, Corporate finance, Debt refinancing, Going concern, Nasdaq compliance, SEC filing, 10-Q
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.